Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Next Previous
X
Search
Trial Profile

A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalantercept (Primary)
  • Indications Adenocarcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors Acceleron Pharma

    • Most Recent Events

    • 03 May 2017 Status changed from active, no longer recruiting to completed.
    • 15 May 2014 According to the Acceleron media release, the results from this trial showed that dalantercept did not produce results sufficient to justify further development as a single agent in endometrial cancer patients.
    • 15 May 2014 According to the Acceleron media release, the data from this trial presented at the 50th Annual Meeting of the American Society of Clinical Oncology in Chicago.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top